StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note released on Thursday. The firm issued a sell rating on the stock.
A number of other research analysts also recently issued reports on SYRS. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright restated a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.33.
Read Our Latest Stock Report on SYRS
Syros Pharmaceuticals Stock Up 20.8 %
Hedge Funds Weigh In On Syros Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Exome Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares during the period. Two Sigma Securities LLC acquired a new position in shares of Syros Pharmaceuticals in the 4th quarter valued at $25,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the 3rd quarter valued at $34,000. 91.47% of the stock is owned by institutional investors and hedge funds.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Recommended Stories
- Five stocks we like better than Syros Pharmaceuticals
- How to Invest in Blue Chip Stocks
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Do ETFs Pay Dividends? What You Need to Know
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- When to Sell a Stock for Profit or Loss
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.